Phaseline

Targets › AQP4

AQP4 (Aquaporin-4): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Genitourinary; next expected readout Dec 2027.

Forms a water-specific channel. Plays an important role in brain water homeostasis. (UniProt, P55087)

Open in Phaseline: the race on AQP4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bio-Thera SolutionsBAT4406F
Anti-AQP4 monoclonal antibody
AQP4Phase 2Optic Neuromyelitis Spectrum Disease; Minimal Change Disease (MCD)Dec 2027

Conditions

Optic Neuromyelitis Spectrum Disease (1) Minimal Change Disease (MCD) (1)

Modalities

small molecule (1)

Companies

Bio-Thera Solutions (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.